Tag
A startup named Generation Lab claims to have developed an injectable drug called 1-Generation that reverses aging in blood, but the article highlights concerns about unproven evidence and red flags in their clinical trial approach.
The article discusses the ethical dilemma of balancing AI development for potential medical breakthroughs, like cancer cures, against concerns about slowing progress. It poses questions about when caution might start causing more harm than good.
This newsletter edition covers two tech stories: the potential night sky disruption from Reflect Orbital's space mirrors and the intellectual property dilemmas when AI designs drugs, as seen with Insilico Medicine's patent practices.
The article discusses how AI is used in drug discovery but patent laws require human inventors, raising tensions between technological advancement and intellectual property rights.
Moderna and Merck announced positive Phase 3 results for intismeran autogene, an mRNA-based individualized neoantigen therapy, in adjuvant treatment for melanoma.
An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.
The article discusses and seeks insights on upcoming AI applications in biology, including labs, startups, and projects that could yield tangible results in areas like supplement optimization and bioactive compounds.
A newsletter digest covering Flock's tightened rules on license plate reader access to combat surveillance abuse, a CRISPR-based cloning advance that could help conservation or create human organ sacks, and a scientist's effort to map children's cells.
Reed Jobs, son of Steve Jobs, manages a $1B+ VC firm called Yosemite that invests in cancer research and biotech, including AI drug discovery and gene editing, with the goal of making cancer non-lethal.
MIT Technology Review's newsletter highlights the selection process for its 2026 Innovators Under 35 list, an investigation into the 'censorship-industrial complex' influencing US policy, and Montana's push to become an experimental medical hub.
A tweet about the AASF 2026 life sciences panel discussion, noting that life sciences are shifting from observation to targeted manipulation of genes, proteins, and cellular states.
Y Combinator shares a Startup School talk in which Science Corp CEO Max Hodak discusses the company's retinal implant that has enabled a blind patient to read a 300-page novel, along with lessons on startup infrastructure, hiring, and judgment.
US researchers used generative AI models Evo1 and Evo2 to design complete virus genomes for the first time, creating 16 novel bacteriophages that can kill E. coli. The breakthrough could enable new disease treatments but raises urgent safety and security concerns.
Moderna's mRNA flu vaccine mFLUSIVA received FDA approval for adults over 50, marking the first mRNA-based flu shot. However, uncertainty remains due to the CDC advisory panel being defunct amid litigation, affecting coverage recommendations.
Olio Labs is introducing its in vivo platform, designed to predict diverse human clinical outcomes from a single high-throughput experiment, bringing predictive validity to drug discovery.
Scientists at Kindred Companion Sciences used CRISPR to knock out the Can f 1 allergen gene in dog cells, successfully creating two gene-edited beagles that don't trigger allergic reactions, as detailed in a paper in The Crispr Journal.
Former OpenAI exec Fidji Simo discusses her POTS battle and her new startup ChronicleBio, which uses AI and massive blood datasets to cure chronic diseases and improve clinical trials.
Former OpenAI executive Fidji Simo discusses her new startup ChronicleBio, which aims to use AI and a biobank of 3,500 blood samples to find cures for chronic conditions like POTS.
Montana's new right-to-try law allows biotech companies to sell experimental drugs after minimal testing, a move that is both hopeful for patients and concerning to ethicists.
The Verge reviews CipherX's Microdot patches, a new pain-free permanent tattooing technology that uses microscopic biodegradable needles to deposit pigment, potentially making tattoos available by mail.